Patients with advanced pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 15, the price target on Tango Therapeutics Inc. (NASDAQ:TNGX) was ...

A phase 3 clinical trial has demonstrated that daraxonrasib significantly improved overall survival and progression-free ...

Background A resemblance of pancreatic tumours to their native tissue architecture remains largely unexplored, while it may ...

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically ...

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression ...

Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits ...

Two nights before the data were announced, “transformative” was the word used to describe the results for RASolute 302 ...

RASolute 302 findings herald a new standard of care in previously treated patients ...

From 2000 to 2021, there was an increase in the incidence of pancreatic adenocarcinoma, which was seen in all age groups, according to a study published online April 14 in JAMA Network Open. Arvind ...

Zenocutuzumab is the first FDA-approved treatment for NRG1-positive NSCLC and pancreatic adenocarcinoma. The eNRGy study demonstrated a 33% overall response rate in NSCLC and 40% in pancreatic ...